eMedicine Specialties > Dermatology > Fungal Infections
Aspergillosis: Follow-up
Updated: Nov 12, 2008
Follow-up
Deterrence/Prevention
Laminar airflow protection and high-efficiency particulate air filters have been reported as effective ways to prevent nosocomial pulmonary infection in patients who are immunocompromised. To prevent primary cutaneous disease, use sterile dressings at catheter sites or other susceptible areas.
Prognosis
When cutaneous involvement occurs in the setting of systemic aspergillosis, the prognosis is poor.
Miscellaneous
Medicolegal Pitfalls
Because of the potentially serious nature of these infections, prompt medical diagnosis is important.
The authors and editors of eMedicine gratefully acknowledge the contributions of previous Editor-in-Chief, William James, MD, to the development and writing of this article.
More on Aspergillosis |
| Overview: Aspergillosis |
| Differential Diagnoses & Workup: Aspergillosis |
| Treatment & Medication: Aspergillosis |
Follow-up: Aspergillosis |
| Multimedia: Aspergillosis |
| References |
| « Previous Page | Next Page » |
References
Zhang QQ, Li L, Zhu M, Zhang CY, Wang JJ. Primary cutaneous aspergillosis due to Aspergillus flavus: a case report. Chin Med J (Engl). Feb 5 2005;118(3):255-7. [Medline].
Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis. Dec 2003;5(4):158-66. [Medline].
Cooke FJ, Terpos E, Boyle J, Rahemtulla A, Rogers TR. Disseminated Aspergillus terreus infection arising from cutaneous inoculation treated with caspofungin. Clin Microbiol Infect. Dec 2003;9(12):1238-41. [Medline].
Koss T, Bagheri B, Zeana C, Romagnoli MF, Grossman ME. Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent. J Am Acad Dermatol. Jun 2002;46(6):945-7. [Medline].
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. Aug 8 2002;347(6):408-15. [Medline].
Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. Jan 1 2007;44(1):2-12. [Medline].
Chakrabarti A, Gupta V, Biswas G, Kumar B, Sakhuja VK. Primary cutaneous aspergillosis: our experience in 10 years. J Infect. Jul 1998;37(1):24-7. [Medline].
Elder D, Elenitsas R, Jaworsky C, eds. Lever's Histopathology of the Skin. Philadelphia, Pa: Lippincott-Raven; 1997:525-6.
Freedberg I, Eisen AZ, Wolff K, et al, eds. Fitzpatrick's Dermatology in General Medicine. 5th ed. New York, NY: McGraw-Hill; 1999:1436-7.
Klein KC, Blackwood RA. Topical voriconazole solution for cutaneous aspergillosis in a pediatric patient after bone marrow transplant. Pediatrics. Aug 2006;118(2):e506-8. [Medline].
Larkin JA, Greene JN, Sandin RL, Houston SH. Primary cutaneous aspergillosis: case report and review of the literature. Infect Control Hosp Epidemiol. Jun 1996;17(6):365-6. [Medline].
Naidu J, Singh SM. Aspergillus chevalieri (Mangin) Thom and Church: a new opportunistic pathogen of human cutaneous aspergillosis. Mycoses. Jul-Aug 1994;37(7-8):271-4. [Medline].
Odom RB, James WD, Berger TG, eds. Andrews' Diseases of the Skin. Philadelphia, Pa: WB Saunders; 2000:415.
Richardson MD, Warnock DW, eds. Fungal Infection. In: Diagnosis and Management. 2nd ed. Blackwell Science: Oxford, England; 1997:113-30.
Further Reading
Keywords
cutaneous aspergillosis, fungal infection, Aspergillus fumigatus, A fumigatus, Aspergillus flavus, A flavus, Aspergillus terreus, A terreus, Aspergillus chevalieri, A chevalieri, Aspergillus niger, A niger, Aspergillus ustus, A ustus
Follow-up: Aspergillosis